AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17302078 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane administered with tidal volume breathing (n=15)
Number of subjects: 30
Study 17302078 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane administered with vital capacity breaths (n=15)
Number of subjects: 30
Study 17302078 — intervention group
Group type: COMPARATOR
Intervention: Both groups (tidal volume and vital capacity)
Number of subjects: 30
Study 12900681 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment applied at LI 4, ST 36 for 20 min, and ST 6, LU 6 for 15 min, 4 hours after the game every night during the competition period
Number of subjects: 21
Study 12900681 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 21
Study 12900681 — intervention group
Group type: COMPARATOR
Intervention: Control group (no acupuncture treatment)
Number of subjects: 21
Study 11180018 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (600 mg daily for 5 days)
Number of subjects: 10
Study 11180018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9366624 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report baseline questionnaire (BQ)
Number of subjects: 863
Study 9366624 — intervention group
Group type: EXPERIMENTAL
Intervention: History of Hormone Use interview (HHU) at the 3-month follow-up visit (HHU3mos)
Number of subjects: 863
Study 9366624 — intervention group
Group type: EXPERIMENTAL
Intervention: History of Hormone Use interview (HHU) at the 3-year follow-up (HHU3yrs)
Number of subjects: 863
Study 8264146 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological cortisol supplementation (20 mg 3 hr prior to test, and 1 mg/hr during test) in panhypopituitarism
Number of subjects: 0
Study 8264146 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological cortisol supplementation in Addison's disease
Number of subjects: 0
Study 8264146 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg 3 hr prior to test, and 0.03 mg/hr during test) in Addison's disease
Number of subjects: 0
Study 2984235 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulfate
Number of subjects: 11
Study 2984235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 30105441 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus use of the IncoStress device
Number of subjects: 80
Study 30105441 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 80
Study 30652487 — intervention group
Group type: EXPERIMENTAL
Intervention: Soil amendments (limestone, organic compost, Ca silicate, zeolite)
Number of subjects: 0
Study 30652487 — intervention group
Group type: EXPERIMENTAL
Intervention: Zeolite and Ca silicate amendments
Number of subjects: 0
Study 30652487 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (no amendments)
Number of subjects: 0
Study 26789012 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glucose suspend (LGS) feature
Number of subjects: 60
Study 26789012 — intervention group
Group type: COMPARATOR
Intervention: Control group (LGS turned off)
Number of subjects: 60
Study 24219012 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once weekly
Number of subjects: 273
Study 24219012 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice weekly
Number of subjects: 273
Study 22669332 — intervention group
Group type: EXPERIMENTAL
Intervention: Ral 60 mg
Number of subjects: 46
Study 22669332 — intervention group
Group type: EXPERIMENTAL
Intervention: Ral 30 mg
Number of subjects: 46
Study 22669332 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3FA (Lovaza) 4 g
Number of subjects: 46
Study 22669332 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovaza 4 g + Ral 30 mg
Number of subjects: 46
Study 22669332 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 46
Study 20055694 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-compound product (calcipotriol/betamethasone dipropionate)
Number of subjects: 18
Study 20055694 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol (Cp) monotherapy
Number of subjects: 18
Study 20055694 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone dipropionate (BD) monotherapy
Number of subjects: 18
Study 18678843 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (tolterodine + behavioral training)
Number of subjects: 307
Study 18678843 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy alone (tolterodine)
Number of subjects: 307
Study 15959750 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurophysiological parameters (EAEP, VEP, MSEP, TSEP, MEP)
Number of subjects: 0
Study 12855088 — intervention group
Group type: EXPERIMENTAL
Intervention: VRSA (virtual stress assessment scenario with a behaviorally realistic motion controlled avatar with sonic feedback)
Number of subjects: 90
Study 12855088 — intervention group
Group type: EXPERIMENTAL
Intervention: VRFP (virtual stress assessment scenario relative to a first-person perspective)
Number of subjects: 90
Study 12855088 — intervention group
Group type: COMPARATOR
Intervention: NTC (No Treatment Condition, just an interview)
Number of subjects: 90
Study 10476617 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozagrel Hydrochloride (400 mg/day, orally)
Number of subjects: 40
Study 10476617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8724617 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms of oral misoprostol every 3 hours up to 5 doses
Number of subjects: 50
Study 8724617 — intervention group
Group type: COMPARATOR
Intervention: 1 mg of vaginal gemeprost every 6 hours up to 4 doses
Number of subjects: 50
Study 8724617 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (misoprostol and gemeprost)
Number of subjects: 50
Study 1680266 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 4-5 mg, intramuscularly
Number of subjects: 100
Study 1680266 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketobemidone (Ketogan) 1-1.5 ml
Number of subjects: 100
Study 6299682 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of THC for 14 nights
Number of subjects: 2
Study 6299682 — intervention group
Group type: COMPARATOR
Intervention: Placebo during four baseline nights and four withdrawal nights
Number of subjects: 2
Study 6299682 — intervention group
Group type: COMPARATOR
Intervention: Placebo during entire period for the second subject
Number of subjects: 2
Study 31090161 — intervention group
Group type: EXPERIMENTAL
Intervention: Transtheoretical model-based motivational interview
Number of subjects: 50
Study 31090161 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 28729311 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 160
Study 28729311 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 160
Study 26434686 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyvalent Bacterial Lysate (PBL)
Number of subjects: 150
Study 26434686 — intervention group
Group type: EXPERIMENTAL
Intervention: Autovaccine
Number of subjects: 150
Study 26434686 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 150
Study 24043299 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg
Number of subjects: 985
Study 24043299 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 985
Study 24043299 — intervention group
Group type: EXPERIMENTAL
Intervention: On-treatment CRP levels
Number of subjects: 985
Study 24043299 — intervention group
Group type: EXPERIMENTAL
Intervention: On-treatment low-density lipoprotein cholesterol levels
Number of subjects: 985
Study 24043299 — intervention group
Group type: EXPERIMENTAL
Intervention: Log change in CRP
Number of subjects: 985
Study 20101166 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor size exceeding 4.5 cm
Number of subjects: 359
Study 20101166 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal cut-off values for tumor size
Number of subjects: 359
Study 20101166 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor size as a prognostic parameter
Number of subjects: 359
Study 20101166 — intervention group
Group type: EXPERIMENTAL
Intervention: Median follow-up of 45 months
Number of subjects: 359
Study 19351691 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial Infarction (MI) within 30 days of randomization
Number of subjects: 13819
Study 19351691 — intervention group
Group type: EXPERIMENTAL
Intervention: Major Bleeding within 30 days of randomization
Number of subjects: 13819
Study 19114736 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity resistance training
Number of subjects: 20
Study 15269191 — intervention group
Group type: EXPERIMENTAL
Intervention: Telithromycin 800 mg once daily for 5 days
Number of subjects: 575
Study 15269191 — intervention group
Group type: EXPERIMENTAL
Intervention: Telithromycin 800 mg once daily for 7 days
Number of subjects: 575
Study 15269191 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin 500 mg twice daily for 10 days
Number of subjects: 575
Study 11351289 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense noise exposure in subjects with asymmetrical hearing loss
Number of subjects: 258
Study 11351289 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense noise exposure in subjects with symmetrical hearing loss
Number of subjects: 258
Study 9226311 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Gy neon ion irradiation
Number of subjects: 15
Study 9226311 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 Gy neon ion irradiation
Number of subjects: 15
Study 7971542 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted self-care program for colds and flu
Number of subjects: 454
Study 7971542 — intervention group
Group type: COMPARATOR
Intervention: Non-users (control group)
Number of subjects: 454
Study 3296867 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (5 mg)
Number of subjects: 20
Study 3296867 — intervention group
Group type: COMPARATOR
Intervention: Metaproterenol (15 mg)
Number of subjects: 20
Study 31402563 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral injection points performed first
Number of subjects: 12
Study 31402563 — intervention group
Group type: COMPARATOR
Intervention: Medial injection points performed first
Number of subjects: 12
Study 29234138 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser + HF
Number of subjects: 0
Study 29234138 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser + HF
Number of subjects: 0
Study 29234138 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphite + Er:YAG laser + HF
Number of subjects: 0
Study 29234138 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphite + Nd:YAG laser + HF
Number of subjects: 0
Study 29234138 — intervention group
Group type: COMPARATOR
Intervention: HF (hydrofluoric acid-etching)
Number of subjects: 0
Study 29234138 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment
Number of subjects: 0
Study 29234138 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphite coating
Number of subjects: 0
Study 25022932 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary Abciximab
Number of subjects: 89
Study 25022932 — intervention group
Group type: COMPARATOR
Intervention: Intravenous Abciximab
Number of subjects: 89
Study 24330347 — intervention group
Group type: EXPERIMENTAL
Intervention: General practice-based vascular risk factor intervention
Number of subjects: 384
Study 24330347 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 384
Study 21541874 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly mystery shop reports with feedback communications (twice monthly)
Number of subjects: 45
Study 21541874 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-monthly mystery shop reports with feedback communications
Number of subjects: 45
Study 21541874 — intervention group
Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 45
Study 18460563 — intervention group
Group type: EXPERIMENTAL
Intervention: GH (0.5 mg iv)
Number of subjects: 16
Study 18460563 — intervention group
Group type: EXPERIMENTAL
Intervention: GH blockade (pegvisomant 30 mg sc)
Number of subjects: 16
Study 18460563 — intervention group
Group type: EXPERIMENTAL
Intervention: GH infusion (45 ng/kg.min, 5.5 h)
Number of subjects: 16
Study 18460563 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemia
Number of subjects: 16
Study 18460563 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 16
Study 17070267 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg nociceptin/orphanin FQ in 10 cc saline
Number of subjects: 18
Study 17070267 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) solution
Number of subjects: 18
Study 15342616 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 patches
Number of subjects: 24
Study 15342616 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 patches
Number of subjects: 24
Study 15342616 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 patches
Number of subjects: 24
Study 15342616 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 24
Study 15342616 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 and 8 patches
Number of subjects: 24
Study 11698834 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.15 mg/kg)
Number of subjects: 150
Study 11698834 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.3 mg/kg)
Number of subjects: 150
Study 11698834 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (1.5 microg/kg)
Number of subjects: 150
Study 11698834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 11698834 — intervention group
Group type: COMPARATOR
Intervention: Control group (no premedication)
Number of subjects: 150
Study 9540175 — intervention group
Group type: EXPERIMENTAL
Intervention: RCT + A (amifostine 500 mg prior to carboplatin)
Number of subjects: 39
Study 9540175 — intervention group
Group type: COMPARATOR
Intervention: RCT alone
Number of subjects: 39
Study 7516250 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (0.6 mg)
Number of subjects: 9
Study 7516250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 7516250 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 9
Study 2660992 — intervention group
Group type: EXPERIMENTAL
Intervention: SR IS-5-MN 50 mg
Number of subjects: 12
Study 2660992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31902294 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand paddles (HPD)
Number of subjects: 20
Study 31902294 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 20
Study 31664940 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline treatment for 12 weeks
Number of subjects: 175
Study 31664940 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 12 weeks
Number of subjects: 175
Study 31664940 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD+/CKD+ patients
Number of subjects: 175
Study 31664940 — intervention group
Group type: COMPARATOR
Intervention: MDD-/CKD+ patients
Number of subjects: 175
Study 29179693 — intervention group
Group type: COMPARATOR
Intervention: Control shoes
Number of subjects: 34
Study 29179693 — intervention group
Group type: EXPERIMENTAL
Intervention: Unloading shoes
Number of subjects: 34
Study 25512670 — intervention group
Group type: EXPERIMENTAL
Intervention: Captain-led and poster STI screening promotion
Number of subjects: 0
Study 25512670 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual health advisor-led and poster STI screening promotion
Number of subjects: 0
Study 25512670 — intervention group
Group type: COMPARATOR
Intervention: Poster-only STI screening promotion
Number of subjects: 0
Study 23562090 — intervention group
Group type: COMPARATOR
Intervention: Canakinumab (2 mg/kg, max 300 mg) monthly for 12 months
Number of subjects: 138
Study 23562090 — intervention group
Group type: COMPARATOR
Intervention: Anakinra (100 mg) daily for 9 months
Number of subjects: 138
Study 21513812 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60mg/day)
Number of subjects: 32
Study 21513812 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT (estriol plus medroxyprogesterone)
Number of subjects: 32
Study 21513812 — intervention group
Group type: COMPARATOR
Intervention: Control (no medications)
Number of subjects: 32
Study 19761455 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐Evaluated Core Competencies Scale (used for assessment)
Number of subjects: 802
Study 19761455 — intervention group
Group type: COMPARATOR
Intervention: Principal components analysis with varimax rotation
Number of subjects: 802
Study 16466708 — intervention group
Group type: EXPERIMENTAL
Intervention: B-vitamin supplements (pyridoxine, riboflavin, and folic acid) for 30 days
Number of subjects: 32
Study 14716707 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 125
Study 14716707 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 125
Study 14716707 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6 PMs
Number of subjects: 125
Study 14716707 — intervention group
Group type: COMPARATOR
Intervention: CYP2D6 EMs
Number of subjects: 125
Study 11300432 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (160 mg/day)
Number of subjects: 1470
Study 11300432 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (500 mg/day)
Number of subjects: 1470
Study 9868087 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril, CoQ10, and VitE
Number of subjects: 50
Study 9868087 — intervention group
Group type: COMPARATOR
Intervention: CoQ10 and VitE
Number of subjects: 50
Study 8280822 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine continuous i.v. infusion (6.25 mg/h)
Number of subjects: 28
Study 8280822 — intervention group
Group type: COMPARATOR
Intervention: Famotidine bolus injection (20 mg every 12 h)
Number of subjects: 28
Study 2827045 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 58
Study 2827045 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 58
Study 29429389 — intervention group
Group type: EXPERIMENTAL
Intervention: Scientist-practitioner program
Number of subjects: 453
Study 29429389 — intervention group
Group type: EXPERIMENTAL
Intervention: Practitioner program
Number of subjects: 453
Study 29429389 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 453
Study 30216294 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected infants
Number of subjects: 1684
Study 30216294 — intervention group
Group type: COMPARATOR
Intervention: HIV-exposed, uninfected infants
Number of subjects: 1684
Study 30216294 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected infants with in utero infection
Number of subjects: 1684
Study 30216294 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected infants with intrapartum infection
Number of subjects: 1684
Study 30216294 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV in utero-infected infants
Number of subjects: 1684
Study 26808865 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw milk with drug residues (DR) containing ceftiofur, penicillin, ampicillin, and oxytetracycline at concentrations of 0.1, 0.005, 0.01, and 0.3 μg/ml respectively
Number of subjects: 30
Study 26808865 — intervention group
Group type: COMPARATOR
Intervention: Raw milk with no drug residues (NR)
Number of subjects: 30
Study 25562388 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized home-based balance and strengthening exercise program with intermittent home-visit support by a physiotherapist
Number of subjects: 71
Study 25562388 — intervention group
Group type: COMPARATOR
Intervention: Previous RCT results
Number of subjects: 71
Study 24089302 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular hyaluronan injection (HS)
Number of subjects: 140
Study 24089302 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic wrist arthroscopy without additional treatment (A-group)
Number of subjects: 140
Study 20522296 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally produced soy/peanut ready-to-use supplementary food (RUSF) at a dosage of 65 kcal/kg/d for up to 8 weeks.
Number of subjects: 2417
Study 18622133 — intervention group
Group type: EXPERIMENTAL
Intervention: Singing bowl therapy (IG)
Number of subjects: 54
Study 18622133 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (KG)
Number of subjects: 54
Study 18622133 — intervention group
Group type: COMPARATOR
Intervention: No treatment (NG)
Number of subjects: 54
Study 18622133 — intervention group
Group type: COMPARATOR
Intervention: Singing bowl therapy (IG) and Placebo treatment (KG)
Number of subjects: 54
Study 16174119 — intervention group
Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP) measurement
Number of subjects: 70
Study 16174119 — intervention group
Group type: EXPERIMENTAL
Intervention: E/Ea ratios (lateral, septal, average)
Number of subjects: 70
Study 16174119 — intervention group
Group type: EXPERIMENTAL
Intervention: Average E/Ea ratio
Number of subjects: 70
Study 14652498 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement containing mixed tocopherols, flavonoids, and docosahexaenoate
Number of subjects: 40
Study 14652498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10962306 — intervention group
Group type: EXPERIMENTAL
Intervention: MLP model
Number of subjects: 656
Study 10962306 — intervention group
Group type: EXPERIMENTAL
Intervention: LR model
Number of subjects: 656
Study 10962306 — intervention group
Group type: COMPARATOR
Intervention: Proportion of free PSA
Number of subjects: 656
Study 8844499 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 28
Study 8844499 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone combined with cyclophosphamide
Number of subjects: 28
Study 1510514 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of rHuEPO (100 U.kg‐1.day‐1) and intravenous iron preparations for 14 days before operation
Number of subjects: 40
Study 1510514 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of rHuEPO (600 U/kg) on preoperative days 14 and 7 and oral iron preparations for 14 days
Number of subjects: 40
Study 1510514 — intervention group
Group type: COMPARATOR
Intervention: Oral iron preparations alone
Number of subjects: 40